CTOs on the Move

Hepion Pharmaceuticals

www.hepionpharma.com

 
Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. T
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Hepion Pharmaceuticals raised $88.4M on 02/18/2021

Similar Companies

Olink Proteomics

Thoroughly validated, rapid, high-throughput multiplexed assays for protein biomarker discovery - high specificity & minimal sample volume requirements

Verve Therapeutics

Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide. Headquartered in Cambridge, Mass., with a research facility in Philadelphia.

Scripps Translational Science Institute

The Scripps Translational Science Institute (STSI) at The Scripps Research Institute (TSRI) aims to replace the status-quo of one-size-fits-all-medicine with individualized health care that is based on the known genetic factors influencing health and disease and that takes advantage of advances in digital technology for real-time health monitoring.

Telik

Telik is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.